1. Statins remain first-line drugs for diabetic dyslipidemia management.
2. Lowering the LDL-C to the desired level is based upon the risk category (LAI Guidelines).
3. Despite adequate statin therapy, residual CHD risk factor remains.
4. Nonstatin drugs to further decrease the LDL-C for the residual CHD risk factors include ezetimibe, PCSK9 inhibitors and bempedoic acid.
5. As Indians have a unique lipoprotein profile with high CHD mortality in the younger age group, our aim should be to target LDL as low as possible.
Dr. S K Wangnoo is a Senior Consultant Endocrinologist at the Apollo Centre for Obesity, Diabetes & Endocrinology (ACODE) of Indraprastha Apollo Hospitals in Sarita Vihar, New Delhi. He is also Honorary Physician Endocrinologist to the President of India. After obtaining the MBBS (1976) and MD Medicine (1981) degrees, Dr. Wangnoo successfully completed the DM (Endocrinology) Examination in 1984.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details